Previous 10 | Next 10 |
Image source: The Motley Fool. TFF Pharmaceuticals, Inc. (NASDAQ: TFFP) Q2 2022 Earnings Call Aug 11, 2022 , 4:30 p.m. ET Operator Continue reading For further details see: TFF Pharmaceuticals, Inc. (TFFP) Q2 2022 Earnings Call Transcript...
TFF Pharmaceuticals, Inc. (TFFP) Q2 2022 Earnings Conference Call August 11, 2022 4:30 PM ET Company Participants Corey Davis - LifeSci Advisors Glenn Mattes - President, CEO & Director Kirk Coleman - Chief Financial Officer Dale Christensen - Director of...
TFF Pharmaceuticals press release ( NASDAQ: TFFP ): Q2 GAAP EPS of -$0.34 misses by $0.02 . Revenue of $28M (+1413.5% Y/Y). For further details see: TFF Pharmaceuticals GAAP EPS of -$0.34 misses by $0.02, revenue of $28M
Phase 2 Inhaled Voriconazole Powder and Inhaled Tacrolimus Powder Programs Continue to Advance Expands R&D Operations with New Austin, TX Facility Recent Feasibility Work Confirms Utility...
Once promising, TFF Pharma is now cash-strapped and stagnant. TFFP badly needs some good news. Q3 interim data may provide that. TFF Pharmaceuticals ( TFFP ) works with a novel method of producing dry powder formulation of known drugs. Licensed from UT Austin and ini...
FORT WORTH, Texas, Aug. 02, 2022 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, today announc...
TFF Pharmaceuticals ( NASDAQ: TFFP ) has announced a significant expansion of its R&D operations through the lease of a new research and development facility located in Austin, Texas. As TFF expands its in-house and partnered research, including applications in biologi...
New Facility in Austin Will Enable Increased Capacity for Internal Pipeline Assets While Accommodating Growing Interest in Partnered Projects Significantly Increases Manufacturing Capabilities to Further Expand Thin Film Freezing Applications FORT WORTH, Texas, July 14, 20...
FORT WORTH, Texas, June 09, 2022 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, today announc...
FORT WORTH, Texas, June 01, 2022 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, today announc...
News, Short Squeeze, Breakout and More Instantly...
TFF Pharmaceuticals Inc - Ordinary Shares Company Name:
TFFP Stock Symbol:
NASDAQ Market:
FORT WORTH, Texas, June 26, 2024 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP) (“the Company”), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology plat...
FDA Provided Constructive Feedback to Help Guide Next Steps in TFF TAC Clinical Development Company to Provide More Detailed Regulatory Update in 3Q 2024 FORT WORTH, Texas, June 24, 2024 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP) (“the Company”), a ...